Notch3 silencing in TKI-resistant TNBC cells induces EGFR dephosphorylation and promotes its intracellular arrest, which increases tumor cell sensitivity to TKI–gefitinib treatment (Diluvio et al., 2018). This evidence concerns the gene EGFR and neoplasm.